


Wyeth

Connecting
Our Work
With The World

Corporate Citizenship
Report 2008



Contents

1	<i>Creating Sustainable Value</i>
2	<i>About Wyeth</i>
3	<i>Tackling Key Issues</i>
4	<i>Embracing Global Challenges</i>
22	<i>Wyeth – A Great Place to Work</i>
30	<i>Protecting Our Planet</i>
40	<i>Building Trust</i>
52	<i>EHS Data Summary</i>
IBC	<i>Mission, Vision and Values</i>

On the Cover

This young girl in South Africa will benefit from her country's newly launched immunization program against pneumococcal disease using *Pneumovax*, the Wyeth vaccine that helps protect infants and young children. Pneumococcal disease is the number one vaccine-preventable cause of death for children.

Reporting Scope

Wyeth's 2008 Corporate Citizenship Report updates the information from our 2006 Corporate Citizenship Report. We considered the Global Reporting Initiative (GRI) Sustainability Reporting Guidelines in preparing this report. For information on GRI, please visit www.globalreporting.org. A GRI Content Index is available on our Web site at www.wyeth.com/aboutwyeth/citizenship. Quantitative data represent aggregated results from Wyeth-owned sites worldwide. No joint venture or third-party manufacturing operations are included in the data.

Feedback

We hope that this Wyeth Corporate Citizenship Report meets your needs for information on our programs and performance. To help us improve the quality of future reports, please send your comments and questions using the business reply card provided with this report. We value your feedback.

Wyeth on the Web

www.wyeth.com

For more information on our citizenship programs, including community outreach and environmental, health and safety efforts, please visit www.wyeth.com/aboutwyeth/citizenship.

Trademarks

Product designations appearing in differentiated type are trademarks.



Recycled

Supporting responsible use
of forest resources
www.fsc.org Cert no. SW-COC-001812
© 1996 Forest Stewardship Council



Creating Sustainable Value

I am pleased to share with you our 2008 Corporate Citizenship Report, which illustrates how the Wyeth community is working to help improve the lives of people around the world.

At Wyeth, we feel a responsibility to develop innovative solutions to address unmet medical needs. But our responsibility does not end there. We also have a responsibility to use our skills and resources to help get medicines to people in need. As we strive to reach a level of commitment and visibility that's higher than ever before, we pledge to continue to put the public and patients at the center of everything we do.

To extend the reach of our efforts, we are collaborating with others who share our vision for a better world. For example, Wyeth and the World Health Organization are working to develop moxidectin – a treatment with the potential to eradicate river blindness in sub-Saharan Africa, parts of Central America and Yemen. More than 37 million people worldwide are infected with the disease. Through our partnership with the GAVI Alliance, we are making available our lifesaving vaccine, *Prevnar*, to millions of children in the world's poorest nations. In the following pages of this report, you can read about these and many other Wyeth programs.



We continue to adapt our business model to encompass economic, social and environmental performance to create sustainable value for our stakeholders and society. To that end, we are forming the Wyeth Sustainability Coalition, a cross-functional team that will set our course, identify our top priorities, and establish metrics and goals for the future. This is a significant step in our Company's evolution; this coalition will integrate sustainability into the core of our operations, which will have an important impact on our business and the public we serve.

Bernard Poussot
Chairman, President and Chief Executive Officer

About Wyeth

Wyeth is a research-based, global leader in pharmaceuticals, consumer health care and animal health care products. Headquartered in Madison, N.J., we are among the largest pharmaceutical and health care products companies in the world, with operating facilities on five continents.

Wyeth is a leader in the discovery, development, manufacturing and marketing of pharmaceuticals, vaccines, biotechnology products, nutritionals and non-prescription medicines that improve the quality of life for people worldwide. Our products are sold in more than 145 countries.

Pharmaceuticals

Our therapies and vaccines include innovative treatments across a wide range of areas, and our research and development programs are focused on finding solutions to some of the world's most critical health problems, including cancer, Alzheimer's disease, arthritis and infectious diseases. By applying the same rigorous standards required for pharmaceuticals to our nutrition business,

we bring parents and caregivers safe, scientifically driven premium products that help infants and toddlers grow strong and healthy.


Consumer Healthcare

Through our commitment to consumers' health and well-being, we have become a leader in more than a dozen important categories, including analgesics, cough/cold/allergy remedies and vitamin/nutritional supplements. Many of our products are number one or number two in their respective categories.

Fort Dodge Animal Health

Like our other businesses, Fort Dodge Animal Health is driven by science, research and innovation. We discover, develop, manufacture and market a wide range of products for livestock and companion animals, including medicines and vaccines for dogs, cats, horses and cattle.

Net Revenue
billions of dollars



Selected Products from Wyeth



Tackling Key Issues

To create sustainable value, Wyeth must look beyond its immediate business interests and help strengthen the well-being of our global community. As such, we engage our stakeholders and partners on many social, ethical and environmental fronts to help create a healthier and more secure world.

Advancing Innovations in Health

As a leading provider of medicines and health care products, Wyeth knows firsthand the challenges of discovering, developing and delivering innovative treatments for people in need in both the developed and developing world. Some emerging compounds that reflect our commitment include a monoclonal antibody to fight Alzheimer's disease and moxidectin, a promising new therapy for river blindness (a major illness in the developing world), as well as three cancer medicines and a treatment for osteoporosis.

Supporting Our People

Only a diverse, empowered and motivated workforce can help Wyeth realize its mission of improving lives and delivering outstanding value to our stakeholders. And our comprehensive training programs, which range from safety training to professional development, are critical tools that spur excellence throughout the Company.

Partnering for a Healthier World

Because health care systems, infrastructures and needs around the world are so complex, all stakeholders – from governments and non-governmental organizations to corporations and academic institutions – must work collaboratively and improve access to medicines. A primary example of such a partnership is our work with the GAVI Alliance, a public/private partnership through which we are making available our pneumococcal vaccine, *Prevnar*, to the poorest countries. Pneumococcal disease kills more children than any other illness.

Preserving Our Environment

Nothing is more important to our health and well-being than preserving and protecting our natural resources. That's why Wyeth has launched many successful integrated programs that both reduce our environmental impact and make Wyeth one of the safest companies to work for in our industry.





A common goal we all share is creating a healthier world for our children and grandchildren.

Embracing Global Challenges

Given the complexity of public health issues in the world today, no single entity – government, industry, academic institution or civic organization – can resolve health care problems alone. Solutions will arise only when all stakeholders, working together, contribute their unique abilities toward a common goal.

Meeting Unmet Global Medical Needs

With the challenges we face, Wyeth will continue to be engaged on the issues, find common ground, and share our knowledge, skills and goals on how to prevent or manage disease, get medicines to the people who need them, and promote good health and well-being among diverse populations.

Wyeth's vision – and our most significant contribution to the global community – is to discover, develop and distribute innovative medicines and vaccines that satisfy unmet medical needs around the world, today and tomorrow.

Discovering and Developing Innovative Medicines

One of Wyeth's key strengths is our pre-eminent capability in research and development (R&D), which is essential to treating patients and serving doctors effectively around the world. In 2007, Wyeth spent approximately \$3.3 billion on research and development. This places Wyeth among the world's leading pharmaceutical companies in R&D spending.

Our primary research areas include pharmaceuticals, biopharmaceuticals, vaccines, consumer health and animal health. With our research teams organized around diseases, not specific compounds, we believe we have a better chance to produce new, innovative treatments.

Areas of focus include:

- Neuroscience
- Vaccines
- Inflammation
- Oncology
- Metabolic Disorders
- Musculoskeletal Disorders
- Hemophilia



Evan Loh, M.D., Vice President, Multiple Therapy Areas, has co-led a project to make Wyeth's clinical development process more productive and efficient.

A Vibrant R&D Pipeline

Our candidates in late-stage development include three novel cancer treatments – a monoclonal antibody to fight Alzheimer’s disease, a next-generation vaccine for pneumococcal disease and a new therapy for river blindness, a major illness in the developing world. Additionally, we expect that *Viviant*, which currently is being developed for the prevention and treatment of osteoporosis, soon will be reviewed by a U.S. Food and Drug Administration advisory committee. Another therapy, *Aprala*, under investigation for postmenopausal vasomotor symptoms and the treatment of postmenopausal osteoporosis, is targeted for regulatory filing in 2009.

Over the past seven years, we have placed more than 100 new candidate medicines into development, with 80 advancing to human clinical trials. Many of these have the potential to be first- or best-in-class therapies. It’s important to



note that 75 percent of the projects in Wyeth’s overall development portfolio are new molecular entities, which represent novel or innovative compounds that could offer significant value to patients and society.

Specifically, we are pressing forward on many fronts, including 10 projects for Alzheimer’s disease (using small molecules, biologics and vaccines) and a wide range of unique compounds with novel mechanisms for treating schizophrenia, bipolar disorder, other cognitive disorders and chronic pain. Though still early, these compounds potentially offer significant improvements compared with current standards of care. In addition, we are investigating innovative therapies in rheumatoid arthritis and asthma.

The demand for these promising new medicines and vaccines is great. For example, current therapies for Alzheimer’s disease provide symptomatic relief but do not alter the underlying disease pathology. There also is a need for safer and more tolerable therapies capable of inducing rapid and long-lasting remission in newly diagnosed patients of chronic myelogenous leukemia. Current antipsychotics for schizophrenia offer adequate symptom relief but often have significant side effects.

Wyeth’s Fort Dodge Animal Health is making progress as well. Through its innovative product development and technology research, the Company not only developed a West Nile vaccine for horses but it also received approval on a new medicine that protects against a particularly virulent strain of calicivirus in cats.

David A. Roth, M.D., Assistant Vice President, Clinical Research and Development, Therapeutic Area Director for Hemophilia Clinical Research and Development in Cambridge, Mass., is among the thousands of Wyeth researchers working to discover and develop innovative medicines.

Streamlining the R&D Process

To address the challenges of getting new drugs approved in an increasingly difficult regulatory environment, Wyeth Research launched a breakthrough initiative in 2008 designed to clarify a new drug candidate's value proposition, develop industry-leading predictive safety and efficacy models, and improve the process for assessing benefit/risk.

This new initiative, which is intended to improve our approval rates and efficiency in years to come, has been added to our Learn and Confirm approach to clinical development, implemented in 2006. In the Learn phase, we strive early in the process to optimize our understanding of the compound to maximize its medical value and justify continued investment. In the Confirm phase, we focus on a timely and efficient confirmation of the drug's safety, efficacy and value for successful registration and launch.

Increasing Scientific Partnerships

Our work in research and development, prevention and wellness helps improve health care around the world. But given the complexities of global health issues, we can't do it alone, and many of the world's people have little or no power to improve their own health. As such, we are increasingly engaging in new and different approaches and collaborations to maximize the potential of our R&D capabilities, products, and human and financial resources. Wyeth continually seeks innovative partnerships and collaborations that bring together world-class scientific and medical resources in academia, industry and government, as well as independent research and patient advocacy organizations around the world. By drawing on the unique knowledge and capabilities of each partner, we hope to streamline or accelerate the discovery and development of new therapeutics that address unmet medical needs.



Wyeth – World Health Organization Fighting River Blindness

Wyeth has been collaborating with the World Health Organization (WHO)/Tropical Disease Research (TDR) to develop moxidectin for potential treatment and eradication of onchocerciasis, or river blindness, a parasitic disease endemic in sub-Saharan Africa, parts of Central America and Yemen. An estimated 105 million people worldwide are at risk, with more than 37 million people already infected.

There is a single question at the core of this collaboration: Can moxidectin inhibit production of microfilaria more effectively than ivermectin, the current tool for onchocerciasis control? If yes, moxidectin has the potential to interrupt the onchocerciasis transmission cycle, making eradication potentially viable.

Final data from a Phase 2 proof-of-concept clinical trial in Ghana on the effect of moxidectin on microfilaria – WHO/TDR sponsored the study, and Wyeth provided the drug and operational support – will not be available until spring 2010.



Photo courtesy of WHO/TDR/CRUMP

Following a review of blinded data to date, however, Wyeth and WHO/TDR have concluded that moxidectin's microfilaricidal/safety profile is comparable with ivermectin. Phase 3 studies are expected to begin in late 2008 in the Democratic Republic of Congo and Liberia.

Wyeth/Cure Neurodegeneration Denmark

The Wyeth/Cure Neurodegeneration Denmark partnership is a novel collaboration that brings together world-class laboratories in universities, hospitals, biotechnology companies and large pharmaceutical companies. The objective is to draw on the strengths of each in addressing a huge unmet medical need – the discovery and development of therapeutics to treat debilitating neurological disorders such as dementia, Parkinson's disease and Alzheimer's. The collaboration, officially established in September 2006 under the Danish Innovation Consortium grant, will continue through 2009.


Translational Medicine Research Collaboration

The Translational Medicine Research Collaboration brings Wyeth together with Scotland's finest medical research centers, including the universities of Aberdeen, Dundee, Edinburgh and Glasgow, and the Scottish National Health Service in a world-leading initiative to develop personalized medicines. Funding in 2008 supported 39 new research projects covering therapeutic areas such as cardiovascular and metabolic diseases, the central nervous system, women's health, inflammation and oncology.

Wyeth is collaborating with the World Health Organization to develop a treatment that will eradicate river blindness, a parasitic disease that is endemic in sub-Saharan Africa, parts of Central America and Yemen.

R&D Recognition

- A team of Wyeth scientists was recognized in July 2007 with the National Medal of Technology, the nation's highest honor for technological innovation, for its role in the discovery, development and manufacture of *Prevnar*.
- In 2007, *R&D Directions* magazine selected Wyeth as the Best Central Nervous System Pipeline as part of the magazine's annual Top 10 Pipeline Report.
- Menelas Pangalos, Ph.D., Vice President, Neuroscience, Wyeth Research, has been named one of the six most distinguished pharmaceutical scientists of 2008 by *R&D Directions* magazine, the leading publication focused on pharmaceutical research and development.



Menelas Pangalos, Ph.D., Vice President, Neuroscience, Wyeth Research, leads an ambitious program that focuses on Alzheimer's disease.

- Wyeth R&D earned the pharmaceutical industry's top honor, the 2008 Prix Galien USA Award for best biotechnology product – the rhBMP-2 dibotermis alfa, marketed as *INFUSE* Bone Graft by Medtronic. Wyeth's *Torisel* and *Tygacil* also were Prix Galien finalists in other categories.
- *PharmaVOICE* magazine readers named Ira Spector, Vice President, Clinical Development Operations, in 2007 and Evan Loh, M.D., Vice President, Multiple Therapy Areas, in 2008 as among the 100 Most Inspiring People in the Life Sciences Industry.
- The Spanish Ministry of Agriculture recently awarded Fort Dodge Spain with a Silver Award for Agricultural Merit in recognition of the division's work to develop a vaccine for bluetongue serotypes 4 and 1, a disease that kills cattle and sheep. It is the first time an animal health company has received this prestigious award.
- Wyeth was recognized at the third annual Scrip Awards ceremony for its scientific and pharmaceutical achievements in 2007. The Company received honors for Best Overall Pipeline and Best New Drug. The pipeline award recognizes the importance of Wyeth's research and development programs that span small molecules, biopharmaceuticals and vaccines. Wyeth is exploring more than 60 new therapies. The best new drug award was for *Torisel*, approved by the U.S. Food and Drug Administration in 2007 for patients with advanced renal cell carcinoma. The Scrip Awards are given out by *Scrip World Pharmaceutical News*, a leading source of global business news in the industry.

Making Medicines Available to People in Need

In everything we do, our goal is to act responsibly – not only for the sake of our stakeholders but for the world at large. One representative example is the rollout of *Prevnar* in the poorest of countries to make this lifesaving vaccine more accessible to millions of children.

Prevnar: Saving Young Lives in the Developing World

Pneumococcal disease kills more infants and children than any other illness – more than AIDS, malaria and measles combined – making it the number one vaccine-preventable cause of death for children. Yet only a small percentage of children at greatest risk of dying are getting the vaccine – *Prevnar* – that is capable of combating this devastating disease. This is due to many factors ranging from lack of available financing to inadequate delivery systems in the least developed countries.

Wyeth is working to make *Prevnar* available to the poorest countries as quickly as possible. In particular, we are collaborating with the GAVI Alliance, a unique public/private partnership to help make available our pneumococcal conjugate vaccine to GAVI-eligible countries – those with an annual gross domestic product per capita of below \$1,000 (www.gavialliance.org).

The GAVI Alliance began by creating the Accelerated Development and Introduction Plan for pneumococcal vaccines (PneumoADIP) in 2002. Wyeth has been collaborating with the PneumoADIP team ever since. In 2006,

the GAVI Board approved funding to make pneumococcal vaccine one of two priority vaccines for GAVI distribution in 2008-2010. More than 30 GAVI-eligible countries have expressed an interest in receiving the vaccine, and GAVI hopes to introduce the first dose in children in early 2009.

In addition to GAVI, a novel funding mechanism called Advance Market Commitments (AMC) has been designed to create predictable markets in poorer countries for future vaccines. The AMC goal is to guarantee demand for next-generation vaccines at steeply discounted prices and then work through GAVI to get those vaccines to countries in need. A pilot AMC was launched in February 2007, with donors pledging \$1.5 billion to support next-generation pneumococcal vaccines. In selecting the target for the pilot, the donors chose pneumococcal vaccine over five other early- and late-stage candidates (HIV, human papillomavirus, malaria, tuberculosis and rotavirus) because of its major potential health impact.



Wyeth is working with the GAVI Alliance – a unique public/private partnership – to bring *Prevnar*, our pneumococcal vaccine for children, to the poorest countries. No other illness kills more children than pneumococcal disease.

Donating Medicines around the World

Wyeth's product donations have supported health programs for those in need in 58 countries. In 2007 alone, we contributed nearly \$15 million in products, primarily to developing countries. We believe such acts of corporate citizenship forge collaborations with global public health organizations, enhance good will and mobilize partners to build needed health care infrastructure in resource-deprived regions of the world.

Partnership for Quality Medical Donations

One way Wyeth helps resource-poor nations is through its founding membership in the Partnership for Quality Medical Donations (PQMD) (www.pqmd.org), an international non-profit membership association for pharmaceutical companies, medical device manufacturers and non-governmental organizations that share a commitment to responsible need-based medical donations.

Medical product donations are an important component of the international health care system used by humanitarian agencies to provide disaster relief, build basic health care infrastructure and combat specific diseases in vulnerable populations around the world.

Wyeth's medicines also have been donated globally in partnership with leading foundations and non-governmental organizations such as MAP International, Heart to Heart International, Project HOPE, National Cancer Coalition, Medical Teams International, Catholic Medical Mission Board, World Vision, Direct Relief International, World Federation of Hemophilia and others.



“PQMD is proud to have Wyeth’s support and leadership as we work to promote quality medical donations worldwide. Wyeth’s membership in PQMD is a reflection of the Company’s commitment to finding quality, lasting solutions to help the millions of people in developing countries who are in desperate need of medicines and health care services.”

Lori Warrens
Executive Director
Partnership for
Quality Medical Donations

Patient Comment

“Thanks to your Company, I didn’t have to make the choice between feeding my children or buying the medication I desperately needed. I would like to take this opportunity to thank Wyeth so much for being there for me when I needed you. I can’t thank you enough for what you have done for my family and for me. Thank you, thank you and thank you for your generosity.”

Sincerely, Kellie P.



Partnership for Prescription Assistance

Wyeth is proud of its participation in the Partnership for Prescription Assistance (PPA) (www.pparx.org) in the United States, which recently helped its 5 millionth patient since its founding in 2005. Working to improve drug affordability and access to those lacking adequate health care coverage, the PPA is a single point of access to more than 475 public and private assistance programs that offer free or nearly free medications. The program offers guidance to patients on how to navigate these available programs and to access more than 2,500 medications.

In addition to our work with the PPA, the Wyeth Pharmaceutical Assistance Foundation in 2007 served more than 145,000 patients, donating products and patient assistance valued at \$143 million. Since 2000, the foundation has donated medicines valued at more than \$1.2 billion.

Travel Packs Aid Medical Missions

Wyeth recently launched a Travel Pack program with MAP International. The program provides medicines and supplies, including Wyeth products, to medical mission teams that can treat many common conditions and diseases that could be life threatening in poor areas.

Honduras

The humanitarian organization Operation Blessing International teamed up with Wyeth to deliver 700 doses of a lifesaving drug to Honduras after an urgent call for special medicine required by hemophiliac patients whose lives were at risk. The doses of Wyeth’s *ReFacto* factor VIII, valued at approximately \$250,000, are an essential clotting factor used to treat hemophilia.

Saudi Arabia

In 2007, Wyeth donated 3,000 doses of *Prevnar* to the Disabled Children's Association in Jeddah for the vaccination of 750 children. This donation was part of an awareness campaign conducted by the association to promote the benefits of vaccination.

Malaysia

Wyeth Malaysia recently launched "A Gift of Love" to help protect needy children from diseases that are vaccine preventable. Through "A Gift of Love," Wyeth is donating *Prevnar* for a period of two years to more than 200 children in six child care centers administered by Malaysia's National Welfare Department.

Thailand

In 2007, Wyeth worked with Bangkok's Municipal Administration (BMA) on a donation of *Prevnar* for children. The BMA encouraged Bangkok residents to have their children vaccinated at the BMA Public Health Service Center free of charge. After vaccination, participating children are immunized against *Streptococcus pneumoniae*, aseptic meningitis, labyrinthitis, sinusitis and systemic infection.

Canada

Wyeth Canada has been partnering with Health Partners International of Canada (www.hpicanada.ca) since 1996 by providing significant donations of a range of medicines – from injectable antibiotics to antidepressants – to clinics and hospitals in places such as Honduras, the Democratic Republic of Congo, Zambia, Malawi, Zimbabwe, and the Balkan countries of Kosovo and Macedonia during their civil strife.

Wyeth makes major consumer health product donations to leading humanitarian organizations such as:

- America's Second Harvest
- Heart to Heart International
- MAP International
- Nourish America
- Operation Gratitude
- Operation Troop Support
- Project HOPE



"I received a package from you today after rolling in from a long mission. I was tired, dirty and hungry, but that box made my day. I thank each and every one of you for what you do. People like you make being here worth it. ... It takes all of us to make America what it is ..."

Estelle T.
U.S. Army, Iraq

Promoting Children's Health

In addition to providing essential vaccines, antibiotics and other medicines to children in need, Wyeth has established and continues to form partnerships with leading health and patient organizations to improve the health and well-being of children around the world.

The Children's Health Fund

Wyeth has a long-standing partnership with The Children's Health Fund (CHF), an organization dedicated to providing health services to medically underserved children in the United States. Wyeth supports CHF's Urban Health Initiative, which focuses on the needs of children and families living in 12 urban areas around the country. Our commitment to the organization includes financial contributions, fundraising assistance, donations of pediatric vaccines and other medicines, and support of public policies to ensure that needy children have access to important medical services and care (www.childrenshealthfund.org).



During one weekend at Barretstown Gang Camp, kids, parents, staffers and Wyeth volunteers created a colorful banner of handprints to reflect their bonds of friendship and fun.

Barretstown Gang Camp

Barretstown, in Ireland, is a specially designed camp for children with serious illnesses – primarily cancer and blood diseases – from Ireland, Britain and throughout Europe. Barretstown provides a unique program of adventure, activities and fun – backed by the medical world – that helps these children regain their confidence and self-esteem. Since 1998, Wyeth has given more than \$1.2 million to the camp. In addition, Wyeth employees in nearly 15 countries volunteer as “caras” – the Irish word for friend – working directly with the children throughout their camp experience. Barretstown has served nearly 12,000 children from 23 European countries since it opened in 1994.

Wyeth Spain Collaborates with Patient Associations on Summer Camps

During the last few years, Wyeth Spain has worked with patient organizations that sponsor summer camps for children. For example, Wyeth's support has enabled numerous children from eight to 16 years of age with juvenile idiopathic arthritis to attend summer camps organized by ConArthritis, the federation of local patient associations. Wyeth also has collaborated with Fedhemo, the Spanish Federation of Hemophilia, to support some of its activities, including summer camp programs. Over the last 10 years, approximately 1,000 campers with hemophilia have learned about their illness and have been given instruction on how to treat it ... while having fun.

Teaching Kids about Germs

For 18 years, Wyeth scientists have shed their lab coats and taken their knowledge to classrooms in the Andover, Mass., area, making science not only informative but also a lot of fun. To date, more than 600 students have attended Wyeth's one-of-a-kind course called “Bacteria around You.” The program, which brings together children from diverse communities, has helped to build friendships and common interests in science.

Supporting Junior Achievement in Ireland

In 2006, our facilities in Newbridge and Grange Castle, Ireland, established a partnership with Junior Achievement, the business and economic education organization for children. Over the last two years, nearly 250 employees have volunteered their time working with more than 4,000 children in local middle and secondary schools. Wyeth employees also have participated in Challenge Science – an exciting science road show that introduces young students to a world of creation and discovery and illustrates the importance of science in today's world.

In addition, the volunteers, teachers and schools all assist transition year students to establish and run an innovative and viable company as part of the Student Innovation Awards program each year. In all of these initiatives, Wyeth volunteers draw from their real-life experiences to enhance lesson plans prepared by Junior Achievement in order to help young people from the local community develop the knowledge and skills they need to succeed.



In the last two years, in partnership with Junior Achievement, nearly 250 Wyeth employees in Ireland have worked as volunteers with more than 4,000 middle and secondary school students to promote science education.

Wyeth Researchers Lecture at University

Wyeth has had a long-standing partnership with Drew University, located near Company headquarters in Madison, N.J., to broaden the depth of the university's programs in the sciences. In 2007, the Company launched the Wyeth Lecture Series in which Drew students and faculty had the unique opportunity to learn from Wyeth scientists who work firsthand in discovering and developing some of the most innovative medicines today. The inaugural program launched in 2007, "A Celebration of Science: The Process of Discovery," discussed the importance of natural products in drug discovery and development. The 2008-2009 series will focus on the identification of agents for treating neurodegenerative and psychiatric diseases.



Jerry Skotnicki, Ph.D., Wyeth's Senior Director, Chemical Interfaces and Alliance Management, judged a science poster contest as part of the Company's science education partnership with Drew University, located near Company headquarters in Madison, N.J.

Being a Good Neighbor in Our Communities

Around the globe, our employees organize and participate in programs that generously support the people and communities where we live and work. These initiatives include everything from highway cleanup and community beautification programs to housebuilding and renovation for needy families to local blood drives to fundraising for medical research – often in partnership with humanitarian organizations such as Community Care Corps, United Way, Arthritis Foundation and Habitat for Humanity.

Each fall, for example, the Company runs a United Way fundraising campaign. In 2008, Wyeth raised more than \$1.5 million from both employee and Company contributions. These contributions support a wide range of local organizations and agencies involved in children's programs, elder care and disaster response, among other initiatives.



Wyeth employees, based at the Collegeville, Pa., facility, volunteer their time to help clear away debris and cut back vegetation at the Valley Forge National Historical Park.

Providing Pro Bono Legal Support

In June 2007, Wyeth's Legal Department launched a pro bono program to provide free civil legal assistance to people and organizations that otherwise could not afford it. Through this voluntary program, nearly 60 Wyeth attorneys and legal staff in New Jersey, Pennsylvania and Massachusetts are engaging in hundreds of hours of public service.

Our volunteers collaborate with, support and back up each other while working with public organizations such as Legal Services of New Jersey (LSNJ), Legal Aid of Southeastern Pennsylvania, Volunteer Lawyers Project of the Boston Bar Association and Pro Bono Partnership. These groups refer our lawyers and staff to a wide variety of counseling and litigation matters, including trademark, copyright, immigration, social security and family law.

Wyeth attorney Bret Parker handled one of the first cases of this program by helping a victim of domestic violence pursue her case in court and achieve a successful settlement. In May 2008, Bret was awarded an Equal Justice Medal by LSNJ and the New Jersey State Bar Association to honor his pro bono work in handling cases and helping Wyeth establish the program.

In its first year, Wyeth's legal volunteers provided more than 350 hours of free legal services for individuals and organizations, and the Company was awarded an International Law Office (ILO) Global Counsel Award for its pro bono work. ILO is one of the world's leading online legal update services. Wyeth is expecting to build on this momentum and expand the program.

Providing Disaster Relief

Pitching In to Help China's Earthquake Victims

Wyeth was quick to respond to the devastating earthquake in China in May 2008. In addition to product donations, the Company contributed more than \$1 million to relief and rebuilding efforts through various humanitarian organizations, the local government, Project HOPE and other organizations. Monies were used to develop “vaccination vans” to store, transport and administer vaccines to those in need. Wyeth also is working with the Soong Ching Ling Foundation to build a school in the affected area.

Wyeth employees in Chengdu and the Sichuan Province closely monitored events on the ground to help provide manpower, medicines and other supplies as needed. Among the 70 employees in Chengdu, 50 organized themselves into two volunteer teams. Those with medical backgrounds went to the local hospital to help physicians treat the injured. The others went to a local relief center to help transport needed goods. More than 2,000 employees – 98 percent of the entire Wyeth workforce in China – donated time, money or both to help in the disaster relief effort.



Many people, including Wyeth employees in China, volunteered to distribute needed medicines and supplies to victims in the aftermath of the devastating earthquake in May 2008.

“The Chinese people are very sensitive to who are friends and who are enemies. When you show caring when they need you most, you become a true friend. Wyeth has earned this country’s friendship.”

Joan Shen, U.S.-based Wyeth scientist who has family and friends in China, volunteered with a medical rescue team in the hardest hit regions after the 2008 earthquake.

Stemming Potential Meningitis Outbreaks in the Dominican Republic

Three humanitarian organizations – Heart to Heart International, Project HOPE and Catholic Medical Mission Board – facilitated the delivery of nearly 600,000 doses of meningitis vaccine to assist people in need throughout the Dominican Republic in late 2007. Wyeth provided doses of its *Meningitec* vaccine, with ancillary supplies of syringes, needles and alcohol wipes provided by Becton, Dickinson and Company.

As a serious communicable disease that causes inflammation around the lining of the brain and spinal cord, meningitis can easily spread among populations. Under the leadership of the Ministry of Health’s Expanded Program of Immunization, children, immigrant populations, prison inmates, military, health care personnel, the poor and other at-risk groups received this lifesaving vaccine from hundreds of sites nationwide. Without this support, these populations would not have access to immunization against meningitis.

Providing Medicines in the Aftermath of Peru's Earthquake

In the aftermath of the 8.0 magnitude earthquake that hit the coast of Peru on August 15, 2007, the pharmaceutical industry stepped in to provide critical aid to the victims affected by the disaster. Wyeth donated 24,000 doses of *Prevnar* vaccine to the Ministry of Health of Peru, enabling it to initiate a vaccination campaign for children. We also contributed \$2.1 million of humanitarian aid to Peru through AmeriCares (an organization with which Wyeth has worked since 1986), including product donations of immunologics, analgesics and multi-vitamins. AmeriCares delivered the emergency airlift of critical medicines and aid to help the earthquake survivors with its partner in Peru, Volunteers for Inter-American Development Assistance. In addition to its contributions in Peru, Wyeth's product donations have similarly supported health programs for those in need in 58 countries.



Wyeth donated 24,000 doses of *Prevnar* vaccine to the Ministry of Health of Peru to initiate a vaccination campaign for children following a devastating earthquake that hit the coast in 2007. The Company also donated humanitarian aid through AmeriCares.

Supporting Our Communities

United Kingdom – Supporting Hospice Care

Wyeth UK is working with a group of local charities – the Alexander Devine Children's Cancer Trust – to help build a local children's hospice that will give both palliative and respite care as well as full support and counseling for the family. Additionally, in 2007, employees of Wyeth Pharmaceuticals in Havant took on the challenge of raising money for The Rowans Hospice.

Germany – Protecting Children

Child protection associations are a powerful lobby for children throughout Germany, fighting against psychological and physical abuse and providing children with as much security in life as possible. Wyeth has supported this important work by cooperating with the local child protection association in Münster. In conjunction with two other local partners, we helped purchase Münster's first mobile child protection minibus. Traveling to local schools, programs focus on preventing violence among children and adolescents through student, teacher and parent projects and conferences.

The Netherlands – Supporting a Psychiatric Hospital in Malawi

Malawi's Zomba Mental Hospital is the only mental hospital in Malawi, one of the world's poorest countries, and lacks manpower and facilities. In 2003, Zomba Mental Hospital en De Mondriaan Zorggroep (Dutch mental care center) began to provide material support and the exchange of experts to help the facility in Malawi. Since 2005, Wyeth Netherlands has supported the initiative of De Mondriaan Zorggroep with a range of services and resources, including help in building a new roof.

Wyeth Gets Involved on Many Fronts in China

As a multinational company with a strong sense of social responsibility, Wyeth has been cooperating with China's local government authorities and relevant social and trade organizations in order to help local communities, providing everything from medicines to support for public health education and continuing education for medical professionals.

Improving Women's and Children's Health

For three years, Wyeth has teamed up with the Ministry of Health to donate *Materna* and *Centrum Kids* products to improve the nutrition and health status of women and children in China's western poor areas. At the same time, Wyeth is working with the Ministry of Health on a prenatal and post-natal health education project for women conducted at dozens of hospitals in 16 cities. The programs include training on nutrition and good health care during pregnancy. Since 2004, approximately 36,000 women have attended the training.

Preventing Transmission of HIV between Mothers and Babies

From 2003 to 2007, Wyeth worked with the National Center for Women's and Children's Health from the Chinese Center for Disease Control and Prevention. The Company donated infant milk formulas for babies born to mothers with HIV in order to help stop the transmission of HIV between mother and baby. The program has served nearly 12,000 mothers.

Establishing Chinese Baby Feeding Guidelines

After a counterfeit incident with infant formula in 2004, consumers in China were in urgent need of practical knowledge on the feeding of babies. Wyeth organized 11 authorities in the field of pediatric nutrition to write the "Chinese Baby Feeding Guidelines" and provided it free to consumers. This booklet was endorsed by various organizations, including the China Consumers' Association, All-China Women's Federation and China Children's Fund.

Setting Hospital Standards and Accreditation

Wyeth recently agreed to sponsor a project to establish China's accreditation standards for hospitals, designed to improve service quality. Under the authority of China's Ministry of Health, Wyeth is working with the China Hospital Association to develop these standards, which will help to evaluate, judge and benchmark the medical service quality of hospitals in China.

Wyeth Named a Caring Company

Wyeth Hong Kong has been officially named by the Hong Kong Council of Social Service a Caring Company for five consecutive years from 2003 to 2008. The award recognizes the Company's commitment to good corporate citizenship and its care for the community in several categories, including corporate and employee giving and employee volunteering.

Wyeth Employees Volunteer at Camp Joy

Team building programs at Wyeth have an added dimension these days since teams now focus their time and energy on helping people and organizations in the community. In the spring of 2008, a team of 11 employees based in Wyeth's Collegeville, Pa., facility volunteered at Camp Joy, a recreational camp for mentally and physically challenged children and adults. The camp is committed to providing structured opportunities for participants to make new friends, have fun, learn and grow. Activities range from group games to physical fitness activities and sports to arts and crafts. Participants also may enjoy a variety of planned field trips. During the course of the team building program, Wyeth volunteers participated in recreational activities with campers.



Shown above are Wyeth employees from the Company's Collegeville, Pa., facility with campers at Camp Joy, based in Schwenksville, Pa., a summer and recreational camp for children and adults with mental and physical disabilities.

Fort Dodge Supports Assistance Dogs and Pet Health

According to the International Association of Assistance Dog Partners (IAADP), about 20,000 individuals in the United States are partnered with assistance dogs. While proper veterinary health care is essential for keeping these companions in top condition, covering the cost of this care can be difficult for those on already tight budgets. To help decrease the financial burden of these veterinary costs, Fort Dodge Animal Health joined IAADP's Veterinary Care Partnership program through which the Company provides monetary support for the organization's emergency fund and supplies animal vaccines at a discount.

With this support, assistance dogs can get the best possible care without owners worrying about covering the bills. Fort Dodge assists IAADP with another goal – promoting public and veterinary industry awareness through education. The Company is publishing a pamphlet that teaches veterinarians about the best treatment protocols for assistance dogs. Some medications, for example, can impair performance, which increases the risk of accidents for owners.

In addition, Fort Dodge helps cover the publishing costs of IAADP's newsletter, which is distributed to members, U.S. veterinary schools and more than 175 assistance dog training programs on five continents. IAADP also holds an annual meeting to address relevant legislation, access-to-care cases, training and other health care issues.

The Power of Teams

Team Building Exercise Helps Needy Kids Roll On

Kids and bikes go together like peanut butter and jelly, but many children living in poverty never experience the joy of pedaling their very own bicycles. Fortunately, this is not the case for hundreds of underprivileged children in the Las Vegas, Nev., and Orlando, Fla., areas. In the spring of 2008, sales representatives at two different product launch meetings participated in team building activities to build 250 bicycles. Wyeth then donated the bikes to local United Way-affiliated agencies that work with needy children. One recipient, Louise Helton of Communities in Schools of Southern Nevada, shared her perspective: “You may see this as a team building exercise,” she said, “but I see this as an army of angels creating opportunities for kids who need them.”

Team Repairs Flood Damage to Boys & Girls Club of Lodi

After sustaining nearly \$1 million in flood damage from a nor’easter in 2007, the Boys & Girls Club of Lodi (N.J.) found more than 170 Wyeth employees from our corporate headquarters volunteering to help restore the facility. The club, which serves 1,800 children per month, was forced to cancel its after-school programs and close its doors to many children who had nowhere else to go. Wyeth volunteers worked on more than 20 projects simultaneously in one day to help revitalize the facility.

“It’s overwhelming to me that people just call up and say, ‘What can we do to help?’ ”

Mike Nardino
Boys & Girls Club of Lodi
Executive Director



More than 170 Wyeth employees volunteered to help restore the Boys & Girls Club of Lodi (N.J.) after it sustained nearly \$1 million in flood damage in 2007. The club serves 1,800 children per month.

*Camaraderie and career opportunities
are two reasons why Wyeth is recognized
as an excellent employer.*



Wyeth – A Great Place to Work

Wyeth is committed to helping its employees and their families meet the challenges and needs of their work and personal lives. In line with our values, the Company makes this commitment – and investment – with the understanding that every person and every job are essential for our success.

Meeting the Work/Life Challenge

Wyeth understands the challenges of managing both a career and a personal life in our complex and fast-paced world. That's why the Company offers a variety of work/life benefits to help employees maintain a reasonable balance.

One indication that Wyeth has been successful in this effort is the 10 consecutive years that we've been named by *Working Mother* magazine as one of the 100 Best Companies for Working Mothers. Another is our biennial employee survey, through which we seek out and respond to employee opinions about their work and work/life experiences.

Studies conducted by independent benefit consultants demonstrate that Wyeth's benefit program is top tier compared not only with leading corporations overall but also with programs offered by other pharmaceutical companies. We work closely with our employees to make sure they take an active role in learning what choices are available and selecting the benefits that best fit their needs.

In addition to health care, insurance and retirement benefits, our efforts to help employees forge a good work/life balance include:

- Family support – Benefits such as paid time off for newborn care, a lactation program for breast-feeding mothers, adoption assistance and dependent care assistance.
- Financial and educational support – Benefits such as a flexible spending account for dependents,

a tuition reimbursement program, tuition scholarships for dependent children and a number of student loan programs.

- Financial consultation services – Free consultation services by telephone for up to 30 minutes per issue. If a Wyeth employee requires additional services, his or her financial consultant may be able to identify a financial advisor or other financial services.
- Legal services – Free consultation services for up to 30 minutes per issue. Employees may call or meet personally with an attorney. Participants in the program receive a 25 percent discount if further legal services are required.

Wyeth also provides a confidential service, prepaid by the Company, that helps employees gain access to valuable health and wellness information and a variety of life management resources and tools. Examples include Financial Fitness for Families, Smoking Cessation, Welcome New Baby and Child Safety at Home.



For 10 consecutive years, Wyeth has been named by *Working Mother* magazine as one of the 100 Best Companies for Working Mothers – a distinction of which we are proud.

Creating Opportunities through Training and Professional Development

In the business of discovering, developing and producing world-class medicines and consumer health products, we always are looking for new ideas and approaches. So we count on the creativity and knowledge of our employees to foster innovation and build on our expertise. With every contribution essential to our success, we do whatever we can to make sure our employees have the training and professional development they need. In various areas of the Company, Wyeth offers an array of training programs and services. Examples of these opportunities include:

- Operational Excellence training.
- Enterprise systems training.
- Eagles Program – A professional and leadership development initiative for top-performing midlevel employees in Wyeth Research.
- Communities of Practice – Where groups of people in Technical Operations and Product Supply (TO&PS) come together to share and learn from one another about a common interest.
- Competency Catalog – A one-stop shop where the training community can learn real-time information about other training programs available around the world in order to share programs with their customers.
- Transformational Coaching – An approach that helps enhance the skills, knowledge and commitment of sales and marketing managers so they can effectively coach their employees to improve performance, respond more quickly to customer needs and develop their own leadership skills.

Top 10 Ranking in *Training Magazine's* Top 125 Companies

In February 2008, Wyeth was honored to rank number three in *Training* magazine's Top 125 Companies for Training. For the first time, the Company's Sales Training & Management Development and TO&PS Organizational Learning groups collaborated on the submission for this award. Wyeth has ranked in the top 20 for six consecutive years.



Wyeth's effort to provide both job-related and career development training has been recognized consistently over the last several years.

Recognizing and Teaching Quality

Wyeth promotes and reinforces the importance of quality and continuous improvement through a visible recognition program that covers pharmaceutical, biotech, and consumer manufacturing, distribution and R&D sites.

The TO&PS Global Recognition Program includes:

- The President's Awards – Gold, Silver and Bronze awards given annually for overall site performance.
- Network Excellence Award – An annual award given to sites for demonstrating network-wide collaborative performance.
- Best Practice Awards – Awards given for projects that result in improvements in the quality of site operations.

A global conference provides an environment to recognize major contributions, share best practices, and identify and plan replication opportunities. The conference is a forum for senior management to emphasize its commitment to sustainable quality, compliance and operational excellence.

Elsewhere around the Company, a variety of recognition programs acknowledges employee and team excellence, the successful implementation of plans, achievement of excellent business results and behavior that exemplifies Wyeth values. These programs include:

- The President's Achieving Excellence award – Recognizes individuals and teams that demonstrate excellence in the implementation of plans and processes while also achieving significant business impact.
- The Above & Beyond program – Enables managers to recognize performance that is implemented effectively, achieves business objectives and is in line with Company values.



“Wyeth operates with the assumption that every person and every job are important and make a difference in achieving our goals of providing innovative and effective medicines and health care products for patients and consumers. A big reason for our success is the fact that the Company plays a proactive role in developing the careers of promising employees through timely training and promoting from within.”

Ernie M. Skinner
Aseptic Set-up Worker
Pearl River, N.Y.

Supporting Global Diversity and Inclusion

Wyeth is committed to fostering a diverse workplace where individuals from different backgrounds, experiences and viewpoints are included in our business decisions. To compete in a global marketplace, the Company must recognize and draw upon the strengths and differences of our people.

Focusing on diversity and inclusion provides Wyeth with the competitive advantage necessary to:

- Enhance and expand our customer relationships and our business.
- Attract, develop and retain the talent we need to succeed.
- Drive increased innovation, creativity and employee engagement.



Wyeth has created an environment in which individuals from different backgrounds, experiences and viewpoints are valued.

Aligning Diversity and Inclusion with Business Priorities

In an era of changing demographics, increased globalization and business process integration, Wyeth must align our diversity and inclusion efforts with our business priorities. Our senior leaders are directly involved with our efforts, and we've helped to define consistent global diversity challenges and key priorities. We seek input from employees at all levels within all functions, which creates opportunities to enhance multicultural competencies. Finally, we carefully monitor programs to determine the short- and long-term effectiveness of our efforts.

Wyeth's Global Diversity Council is a senior leadership group that provides broad oversight for the Company's global diversity and inclusion strategy and sets diversity priorities.

Wyeth's Corporate Diversity Department provides expertise and leadership to drive global priorities and ensure alignment with short- and long-term business goals.

Divisional and Business Unit Diversity Councils determine diversity strategies, initiatives and plans to meet their specific needs – in alignment with company-wide objectives.

Global Constituency Groups, representing various segments of our employee population, provide Wyeth with feedback about how to attract, retain and engage diverse talent and enhance business performance. Work is under way for eight different groups – focusing on Women, Men, Asians, Blacks, Hispanics, Native/Aboriginal People, Gay/Lesbian/ Bisexual/Transgender Individuals and People with Disabilities.

Global Priority Teams are convened, as needed, to address diversity and inclusion priorities critical to our employees and our business. Currently, Priority Teams are working on issues related to Diverse Employee Representation and Work/Life Integration.

Employee Networks are inclusive, voluntary, employee-established groups that allow individuals who share common interests to gather and collaborate – while advancing the Company’s business, talent management and diversity goals. Currently, eight Employee Networks have been established, including four Women’s groups, two African-American networks, a Hispanic/Latin network, and a group to support Gay/Lesbian/Bisexual/Transgender employees and allies.

Diversity and Inclusion Training, Development and Opportunity

To support retention and recruitment of the global workforce necessary to drive our future business success, Wyeth is proud to offer employees the opportunity to participate in various diversity-related inclusion and training programs, including: Women in Leadership, the Wyeth Research Diversity Leadership Development Program and the Career Management Program.

Other skills and awareness training programs include:

- **Civil Treatment** – This is a mandatory training program designed to provide employees with the skills needed to build and maintain a workplace that recognizes cultural diversity and is free of harassment and discrimination.

- **Wyeth Management Committee Mentoring Program** – Participants in this company-wide initiative, now in its third year, form relationships that encourage mutual learning. The program focuses on providing career development and professional guidance – and on creating opportunities for networking. In 2008, 13 employees (10 women and three people of color) are being mentored by some of the Company’s most senior executives – including our Chairman, President and CEO.
- **INROADS Summer Internships** – Internships are offered each year to high-potential minority students. (INROADS is a nationally recognized, non-profit organization focused on the early identification, development and placement of professional minority talent in business and industry.) These placements are in addition to the Company’s formal Internship Program, which offers employment to minority- and non-minority students each summer.

Giving Back to the Community

Diversity-related philanthropy plays a key role in Wyeth’s overall corporate citizenship strategy. The Company has developed long-standing partnerships with a number of community-based organizations that focus on the developmental needs of women and people of color. Specific examples include:

- **Catalyst** – For 25 years, Wyeth has provided financial support for this leading research and advisory organization, which works with businesses and the professions to build inclusive environments and to expand opportunities for women at work.

- Jersey Cares – For more than 10 years, Wyeth has partnered with this organization by providing financial contributions and countless employee volunteers to meet compelling needs and encourage civic engagement primarily in minority communities.
- University of Maryland, Baltimore County – In 2006, Wyeth formed a multi-year, multi-level partnership with this institute of higher education. Wyeth's support includes graduate fellowships to fund student research in the University of Maryland, Baltimore County's (UMBC) Chemistry and Biochemistry departments and sponsorship of UMBC's annual life science symposium.
- Executive Leadership Council – Wyeth supports this non-profit organization, which is dedicated to providing African-American corporate executives with networking opportunities and leadership resources.
- The Urban League of Philadelphia – Wyeth endowed this organization with a Wyeth Pharmaceuticals Scholarship Fund, awarded in \$10,000 increments over a four-year period (2005 through 2008).
- United Negro College Fund – Wyeth partners with this organization to sponsor Wyeth scholarships for minority students who are pursuing health- or business-related careers.

Increasing Supplier Diversity

Wyeth's Supplier Diversity program offers opportunities to small businesses and those owned by minorities, women, veterans and service-disabled veterans who can supply high-quality goods and services at competitive prices. By providing opportunities to diverse businesses, we create a supplier base that reflects the communities we serve and contributes to their economic growth and expansion. By fostering a sense of community among diverse suppliers in this way, we also achieve innovation and cost-effective solutions.

In February of 2008, Wyeth partnered with other industries to sponsor workshops in Puerto Rico to help our current suppliers attain Small Business Administration certification. A fourth quarter 2008 launch of Supplier Diversity Awareness e-learning for all procurement personnel in the United States and Puerto Rico is intended to increase supplier diversity awareness and show how our diversity efforts help us uphold our contracts with the U.S. government.



AmerCares staff photo

More than 100 employees from Wyeth Consumer Healthcare volunteered their time to help address community needs at several locations in Morris County, N.J.

Women in Leadership

Nearly half of Wyeth employees are women, and, in increasing numbers, they are fulfilling leadership roles in the Company. To support the leadership development of talented women at Wyeth, the Company has offered many of them the opportunity to enhance their careers by attending Women in Leadership training seminars. Participants explore their own key strengths, communication styles and perspectives on career possibilities. Presenters include successful Wyeth female executives discussing their own strategies and experiences.

Because of this kind of training, as well as proactive recruiting efforts, women today are increasingly taking on leadership and management positions in all areas of the Company – from research scientists who direct major development programs for new medicines to product and marketing management leaders to executives in communications, finance, human resources, legal affairs and corporate governance.

Actively Searching for Diverse Talent

Wyeth employees provide the diversity of thought, experience, background and culture necessary to strengthen our organization and, ultimately, drive our business success. We are committed to increasing the strength, depth and diversity of our employee base by attracting, developing and retaining top talent at all levels. In support of these goals, Wyeth attends the following diversity career events: National Black MBA Association, The Society of Women Engineers, National Society of Hispanic MBAs, Black Data Processing Associates, National Sales Network, Urban League Career Fairs and NAACP Career Fairs. Wyeth also posts promotional and branding advertisements in the following diversity publications: *Black MBA*, *Black Enterprise*, *Hispanic Business*, *Working Mother* and *DiversityInc*.



Mary Lou Bell led the Wyeth BMP Team that developed and registered rhBMP-2. Mary Lou, along with Mikael Dolsten and John Wozney, accepted the 2008 Prix Galien USA Award for *INFUSE* Bone Graft on behalf of Wyeth and the project team.

“I’m encouraged to see that there is increasing diversity at all levels of management and a greater focus on strengthening this trend. With a wider range of people and ideas, combined with more responsibility and authority at the project team level, I’m seeing the benefits of diversity every day. Clearly, management is committed to creating opportunities, and the old, artificial barriers are breaking down.”

Mary Lou Bell
 Director, Project Management
 Wyeth Research
 Cambridge, Mass.
 (19 years at Wyeth)

Wyeth understands the critical importance of reducing our impact on the environment for the sake of generations to come.



Protecting Our Planet

As a leading health care company, we recognize that preserving and protecting our environment has a profound impact not only on our health and well-being but also on our ability to sustain life on our planet in the future.

As such, we are firmly dedicated to advancing comprehensive programs that address relevant environmental, health and safety (EHS) issues. That's why our environmental health and safety professionals are represented in all Wyeth's business units and facilities. These professionals make sure EHS concerns are incorporated into all process and operational activities and improvements.

Wyeth's vision – leading the way to a healthier world – therefore is being carried out broadly. It is a concerted effort to reduce the Company's environmental impact on our planet and operate our business in a safe manner.

Reducing Environmental Impact

Climate change is the most important global environmental issue of our era. Wyeth's climate change initiatives are focused on conserving energy and reducing greenhouse gas emissions, which primarily are carbon dioxide (CO₂). Since 2000, our programs to reduce CO₂ and other emissions, as well as water use and waste, have had a significant, positive environmental impact.

The reasons for our success in conserving energy and reducing our environmental impact are many. Key among them is our integrated approach that touches every employee and department at Wyeth. This integrated approach includes comprehensive compliance programs; ongoing assessments of our progress; peer company benchmarking; a focus on our people; rewards and recognition for EHS initiatives; training and education; the communication of high standards; management systems; and precise metrics.

Safety results from 2000 to 2007 are as follows:

- Lost-Time Injury Case Rate – *Down 68%*
- Total Injury Case Rate – *Down 57%*

Environmental results from 2000 to 2007, normalized per dollar revenue, are as follows:

- CO₂ Emissions – *Down 37%*
- Water Use – *Down 44%*
- Hazardous Waste Generation – *Down 67%*
- Solid Waste Generation – *Down 68%*
- Ozone Depleting Substance Releases – *Down 55%*
- SARA 313 Releases – *Down 88%*


These achievements resulted from numerous initiatives conducted throughout Wyeth, which have helped the Company become more sustainable. We have achieved this formidable success because EHS programs are being integrated into all aspects of our business – from manufacturing sites and R&D labs to information and management systems to sales and marketing activities to human resources development and training programs.



Numerous environmental initiatives at Wyeth have helped the Company become more sustainable.

Carbon Dioxide Emissions


million kilograms per billion dollars sales



By increasing the efficiency of our operations and utilizing highly efficient cogeneration plants at several major facilities, Wyeth's carbon dioxide emissions (normalized per dollar revenue) have steadily decreased. The 2007 levels represent a 37 percent decrease from 2000, as measured by globally accepted emissions protocols.

Water Use

million liters per billion dollars sales



Through many innovative water conservation programs, Wyeth has decreased water use by 44 percent since 2000 (normalized per dollar revenue). In absolute terms, even though the Company has shown continued revenue growth, approximately the same volume of water is used year after year in the manufacturing of our products.

Using Resources Efficiently

There are many benefits to being a more sustainable enterprise – one of them is a competitive advantage. By preserving resources, we not only help the environment, we're also reducing our costs; creating innovations in our research, manufacturing and marketing processes; and engaging our colleagues and partners in making business practices more efficient.

Energy Conservation

While reducing energy is an important achievement by itself, the Wyeth Energy Program also reduces our costs, enabling us to invest resources in more productive ways. Since the beginning of 2003, Wyeth has completed approximately 400 energy projects. As a result, we have been able to reduce the environmental impact and control the utility costs of our operations throughout the world. Since its inception in September 1997, the Wyeth Energy Program has realized a savings of well over \$100 million.

Our use of cogeneration at five of our facilities is a key factor in our efforts to conserve energy. Cogeneration produces power and heat simultaneously using one primary fuel, reducing CO₂ emissions significantly and achieving efficiencies of 70 percent and more. We have approximately 45 megawatts of cogeneration capacity. In 2007, cogeneration provided approximately 22 percent of our electrical requirements.

Green Design and Construction

Wyeth is focused on minimizing the environmental footprint of all our buildings, including the review of capital project designs that improve energy efficiency and environmental performance. The Company collects and evaluates data on new building designs as well as existing facilities in order to quantify and reduce energy and water use, emissions and resources used in operations.

In addition to assessing the environmental impact of our R&D and manufacturing facilities, we continue to look for ways to reconfigure existing and new office buildings. Wyeth UK, for example, has signed a 15-year lease for 115,000 square feet of office space at GreenPark in Reading, England, due to be completed in late 2009. Approximately 400 employees will relocate to the new office, which will incorporate several environmental design features with the goal of obtaining an “Excellent” BREEAM (Building Research Establishment Environmental Assessment Method) rating. This rating provides a rigorous assessment standard to buildings, including management, health and well-being, energy, transport, water, material and waste, land use and ecology, and pollution.

Dramatically Increasing Product Yields

Over the past 15 years, our Biotechnology Development group has achieved a 100-fold increase in product yields per batch, based on significant investments in process improvements. This means a facility can produce 100 times more product with the same amount of water and carbon-based materials. Due to these improvements, Wyeth can dramatically reduce the need for additional production space and natural resources.

In the production of vaccines, yields have improved 10-fold, which not only lowers costs but also helps reduce our impact on the environment. With higher yields, the Company is using substantially lower amounts of ingredients per batch, including water and carbon-based raw materials, which reduces costs and improves process sustainability.

This significant progress in product yield clearly suggests that environmental principles have become a top priority in our manufacturing facilities, which are continually creating strong, robust processes and standards to reduce material use, optimize efficiency and streamline our manufacturing capabilities.




“We’re developing a new way of reducing risks and including green chemistry when we develop compounds – a cost-effective and environmentally efficient model that improves our understanding and uncovers problems earlier so there are no surprises when we launch new medicines.”

John Dillon, Ph.D.
Vice President, API Technology Operations
Pearl River, N.Y.

Hazardous Waste


million kilograms per billion dollars sales



While hazardous waste generation has decreased by 67 percent since 2000 (normalized per dollar revenue), the last four years have seen a slight increase in the absolute total of hazardous waste generated. Nevertheless, Wyeth continues to substitute less hazardous materials in our products and processes and recovers and recycles solvents wherever practicable.

Solid Waste

million kilograms per billion dollars sales



By working with our waste contractors and engaging all our employees, Wyeth has reduced the volume of solid waste disposed by 53 percent since 2000 (normalized per dollar revenue). In addition to waste reduction, our sites are capturing greater volumes of waste material (such as paper, metal, wood and plastics) for reuse and recycling.

Applying the Principles of Green Chemistry

In 2007, Wyeth formed the New Product and Process Development group to streamline and improve late-stage development and the launch-readiness of our pipeline products. This effort includes evaluating ways to integrate environmental improvements and apply the principles of green chemistry. Specifically, this means choosing, and where possible cutting back, pharmaceutical ingredients and process chemicals, such as solvents, to optimize efficiency and reduce environmental impact.

As green chemistry principles are integrated into the product development cycle, we are creating stronger, more robust processes that move us toward more sustainable manufacturing operations while maintaining our high standards of product and process quality and compliance. To strengthen our green chemistry efforts, we have joined the American Chemical Society's Green Chemistry Institute (ACS-GCI) Pharmaceutical Roundtable, which is a partnership between the ACS-GCI and member pharmaceutical companies.

Pharmaceuticals in the Environment

Wyeth conducts studies on our active pharmaceutical ingredients (API) and sponsors research on new technologies capable of removing APIs from wastewater. We also support efforts to raise consumer awareness about the potential negative environmental impact associated with improper disposal of unused medicines.

Through our internal Pharmaceuticals in the Environment Committee, we assess and minimize the environmental impact of our prescription and over-the-counter APIs from our manufacturing operations. Over the last few years, we have invested nearly \$4 million in these efforts. One key example is our Newbridge, Ireland, facility,

which now produces no detectable APIs in wastewater effluent. Wyeth will be participating in a new National Science Foundation Center research program in the areas of treatment technology and emerging contaminants that will include leading academic and business partners.

Lean and Clean Training

To drive sustainable practices throughout Wyeth, the Company has combined training in Operational Excellence (e.g., Lean Six Sigma techniques) with EHS concepts so our employees understand common approaches to streamline and improve processes. “Lean and Clean Training – Seeing All Wastes” was conducted from May to September 2008.

By combining EHS and Lean practices, we not only can more effectively meet key environmental, health and safety commitments, we also create significant new improvement opportunities, which can lead to additional savings in materials, energy and water consumption.

Using Less Packaging

Over the last five years, packaging changes on some Wyeth items have resulted in significant decreases in raw material usage. Recent Wyeth accomplishments include the elimination of inner pack trays for respiratory products, a refill package redesign for *ChapStick*, and entirely new packaging for multivitamins *Centrum Silver* and *Centrum*.

The new, more sustainable *Centrum Silver* and *Centrum* packaging, for example, has totally eliminated the use of polyvinyl chloride, or PVC, plastic and has reduced the shipping case size for each item. Due to the smaller shipping cases, we estimate that 124 fewer truckload shipments will be required in 2008, and 17,000 gallons of diesel fuel will be saved.

The total packaging removed from *Centrum* cartons will amount to more than 120,000 pounds

in 2008, including all primary and secondary packaging materials. Many of our large retail customers are responding favorably to these changes, as they promote supplier sustainability initiatives, measure progress carefully and recognize solid achievements. In a competitive business climate, therefore, sustainability is good for business, good for the environment, and good for more trusting and credible relationships with customers and consumers of our products.


Green Office, Meetings and Dining

As part of our ongoing efforts to reduce our environmental impact, we are including and promoting green practices at Wyeth meetings and at our dining facilities – encouraging our colleagues to do “the little things” every day. For example, Wyeth encourages employees to bring reusable water bottles and coffee mugs to work to help reduce the use of disposable plastic water bottles and Styrofoam cups.




By simply using a reusable coffee cup, the average employee will avoid disposing of approximately 500 Styrofoam cups annually.

Lost-Time Injury Case Rate
per 100 employees



The lost-time injury case rate per 100 employees at Wyeth is among the lowest in the pharmaceutical sector and has decreased steadily over the last seven years. With the adoption of a management systems approach to safety, Wyeth's performance is based on robust systems and international best practices.

Total Injury Case Rate
per 100 employees



Many of our sites now are certified to a recognized safety management system such as OHSAS 18001 or OSHA VPP. With the external certification of our safety systems, Wyeth is working beyond compliance to provide an ever safer workplace for all employees and for visitors to our sites.

In addition to using reusable water bottles and coffee mugs, Wyeth encourages:

- Buying healthier, locally grown foods for cafeterias and meetings.
- Turning off lights when leaving offices and conference rooms.
- Using environmentally sound cleaning products.
- Maintaining facilities and property with environmentally sound techniques.
- Replacing light switches with motion sensors.
- Utilizing e-mail vs. paper copies and printing double-sided copies.
- Replacing paper and plastic products with china, glassware and silverware.

Alleviating Traffic/Improving Air Quality

In 2008, Wyeth became the first pharmaceutical company in the United States to introduce all four-cylinder engine vehicles to its field sales force. This will result in a more than 20 percent increase in fuel economy, dramatically reducing Wyeth's emissions and carbon footprint.

Wyeth locations make a conscious effort to reduce the environmental impact of employees' commute to and from work through programs that include carpooling, vanpooling, public transit, shuttle bus services, biking, walking and other means of environmentally sensitive, energy-efficient travel.

In 2007 alone, these efforts resulted in the elimination of nearly 5.5 million vehicle miles traveled, prevented 5.2 million pounds of carbon dioxide emissions from being emitted and achieved a savings of nearly 270,000 gallons in fuel. More than 300 employees who vanpool, over 1,000 carpoolers, 167 transit riders and nearly 50 bikers delivered these impressive results. But if employees must drive themselves to work, the Company shares ideas on how people can improve the fuel efficiency of their cars.

Ensuring the Safety of Our Employees

Wyeth sites around the world have been recognized by external agencies with awards for superior employee safety programs. The reason is not simply because we like to win awards. It is because the health and well-being of our employees are critically important to us and to our business success. As a result, we have improved our safety record and will keep pursuing greater improvements for as long as we're in business.

EHS Management Systems Certification

Throughout the world, Wyeth facilities are earning third-party certification that substantiates the quality and effectiveness of our EHS management systems.

In the United States, many of our operating sites are partnering with the U.S. Occupational Safety and Health Administration (OSHA) to attain Voluntary Protection Program (VPP) certification, which demonstrates a site's commitment to excellence in its safety programs. Worksites with VPP certification status have a lost workday incidence rate at least 50 percent below the industry average.

Our manufacturing facility in Andover, Mass., achieved OSHA's VPP STAR status in 2008, and our Pearl River, N.Y., manufacturing and research facility was the 2,000th site nationally to be awarded STAR certification. Our Richmond, Va., and Vonore, Tenn., facilities also have been VPP certified. Sites in Princeton, N.J.; Cambridge, Mass.; and Guayama, Puerto Rico, all are striving to achieve VPP certification within the next year or two.

In November and December 2007, our vaccine development and manufacturing facilities in North


Wyeth President's Award Winner

The Wyeth President's Award for EHS Excellence is presented annually to a facility or group of facilities that achieved EHS excellence and have embraced sustainability. The most recent winner of this award is Wyeth Medica in Newbridge, Ireland, which boasts a state-of-the-art wastewater treatment plant, top-flight recycling and energy conservation programs, outstanding employee safety programs and numerous outreach efforts to support the community. As part of the award, the site was able to donate \$5,000 to two local non-profit organizations in the Newbridge area.



Wyeth Medica in Newbridge, Ireland, earned the President's Award for EHS Excellence because of its state-of-the-art wastewater treatment plant, its recycling and energy conservation programs, and its outstanding employee safety record.


Ozone Depleting Substance Releases
kilograms per billion dollars sales



Wyeth is committed to reducing the use of ozone depleting substances (ODS) in our processes. Wherever possible, Wyeth will substitute more environmentally friendly alternatives for Class I ODS. As a result, use of Class I ODS at Wyeth has decreased by 69 percent (in absolute terms), and emissions of all ODS (normalized per dollar revenue) have decreased by 55 percent since 2000.

SARA 313 Releases

kilograms per billion dollars sales



Wyeth has significantly decreased the amount of toxic chemicals it uses in accordance with Section 313 of the Superfund Amendments and Reauthorization Act (SARA) in the United States. From 2000 to 2007, the Company achieved an 88 percent decrease in SARA 313 chemicals.

Carolina received the state’s STAR certification – a state-run version of OSHA’s VPP. The North Carolina Department of Labor estimates that achieving STAR certification takes an average of four years from start to finish. Both facilities – the Sanford manufacturing site and The Research Triangle Park site – achieved STAR status in less than three years, and Sanford was the first pharmaceutical manufacturer in the state to attain this distinction in safety.

Wyeth facilities in **North America** that already have achieved certification include: the chemical pilot plant at Rouses Point, N.Y.; Chazy, N.Y., the first Wyeth site to achieve VPP re-certification (March 2008); and the Montreal, Canada, facility, which is certified to both International Organization for Standardization (ISO) 14001 and Occupational Health and Safety Assessment Series (OHSAS) 18001.

Internationally, the manufacturing facility in Grange Castle, Ireland, achieved OHSAS 18001 certification in late 2007.

The following international facilities already have achieved third-party certifications:

In **Europe**, our facilities in Algete, Spain; Aprilia, Italy; Grange Castle, Ireland; Newbridge, Ireland; and Weesp, Netherlands are ISO 14001 certified. In addition, Algete, Askeaton, and Newbridge are certified to both OHSAS 18001 and the Eco-Management and Audit Scheme, while Grange Castle is certified to OHSAS 18001.

In **Asia**, our facilities in Canlubang, the Philippines; Shanghai, China; and Singapore are certified to both ISO 14001 and OHSAS 18001.

In **Latin America**, our Itapevi, Brazil, facility is certified to both ISO 14001 and OHSAS 18001.

Improving Driver Safety

Driving a motor vehicle generally is acknowledged as a high-risk activity. For 18 years, Wyeth has been a leader in driver safety in the United States with a

program that has realized a steady reduction in the number of vehicle collisions. From 2004-2007, the number of collisions was reduced by more than 600, which saved over \$10 million. Building on this success, the Wyeth Global Driver Safety Program is a comprehensive effort to help keep those individuals around the world who drive Company vehicles, as well as other road users, safe. The components of this program include behind-the-wheel and computer-based training along with an extensive data management system through which we can identify the types of accidents our people are having, as well as location, frequency and severity, so we can focus on our priorities.

The program is being implemented in two phases: Phase 1 (2007-2008) introduces the program within EMEA/Canada. Phase 2 (2008-2009) focuses on Asia/Pacific and Latin America. To reinforce the importance of this driver safety initiative, Wyeth is developing a comprehensive program designed to recognize excellent performance for teams and individuals around the world.

Remediating Legacy Sites

Like most major industrial corporations, Wyeth is involved in the investigation and remediation of sites where we have cleanup obligations under a variety of federal, state, and local laws and regulations. The vast majority of our remediation liability derives from entities that we acquired and for which we have successor liability – not from impacts caused during our operation of these sites. In 2008, we had a total of 74 reserved remediation sites – of which 43 percent are former American Cyanamid sites, 82 percent are in the United States and 40 percent are multi-party Superfund sites. The current reserve total is \$269 million, down from \$424 million 10 years ago, a reduction due to spending and aggressive management to move sites through the cleanup phases to productive use.

EHS Recognition

- The Health and Safety Authority in Ireland awarded our Grange Castle facility the All Ireland Health and Safety at Work Week Award 2007.
- The Irish Business and Employers Confederation awarded the Newbridge, Ireland, facility the Responsible Care Award 2007 for the site's Behavioral Awareness for Safety and the Environment Program. Newbridge also won The Royal Society for the Prevention of Accidents Silver Award in 2007.
- Our Pharmaceuticals site in Guayama, Puerto Rico, was presented with two awards from the Puerto Rico Manufacturers Association for safety.
- The Singapore facility recently earned its second Gold Safety Performance Award from the Singapore Ministry of Manpower.
- The Department of Environmental Protection Commissioner in New Jersey recognized Wyeth in 2008 for environmental stewardship and the integration of environmental practices that exceeded environmental requirements at our Bridgewater, N.J., remediation site.
- Pearl River, N.Y., was awarded the 2007 and 2008 Innovator Award – Regional Commuter Choice Awards by the New York Metropolitan Transportation Council and the 2008-2009 Crystal Award (Clean Air Champion) by Clean Air New York.
- The Madison and Princeton, N.J., sites were awarded the 2008 New Jersey Smart Workplace Award, Platinum level, the highest level of achievement.



*Each and every day, we must
earn the trust of the people
who rely on our products
and our integrity.*

Building Trust

Whether it's the quality of medicines and health care products we develop and deliver to patients, the work environment we offer to our employees and suppliers or the highest standards of integrity we uphold as a corporate citizen of the world, we recognize that our success is based on earning the trust of all our stakeholders every single day.

Improving Product Quality, Consistency and Safety

Above all, as a provider of innovative medicines, patient safety is our highest responsibility. That's why we have established a rigorous evaluation and testing program that goes beyond meeting mandated regulations, starting at the earliest stages of drug discovery and continuing after our medicines go to market. We want all our stakeholders to know we are doing everything possible to strengthen the trust that patients and consumers have given us when they choose our prescription or over-the-counter products.

Gathering and Reporting Safety Data

Today, about 300 professionals are part of the Global Safety Surveillance, Epidemiology and Labeling (GSSEL) function at Wyeth, making sure the Company meets all its obligations and complies with all applicable regulations. These analysts examine every aspect of our medicines' safety, from the first dose a patient takes in a clinical trial through the life of the product in the marketplace.

GSSEL prepares, evaluates and distributes adverse event information on individuals and in summary mainly to regulatory agencies, Wyeth affiliates, investigators and business partners. Our safety experts routinely monitor the safety information from our clinical trials as well as reports from professionals and consumers who prescribe or take our medicines.

In addition, we have epidemiologists who look beyond Wyeth's safety information and examine government, insurance and medical databases to add to our understanding of the safety of our products. We also have experts in risk management who look at our products' risks in the context of their benefits. These experts may put in place robust plans to mitigate patient risks to assure that those who take our products will reap the maximum benefit and the least risk. Important benefits and risks are communicated through a product's label, which is updated regularly in every country where the product is prescribed.

Improving Product Quality/ Supply Chain Management

Wyeth has a proactive focus on product quality that includes three key elements – product knowledge, Quality by Design (QbD) and risk management systems – that are designed to deliver sustainable, compliant and in-control product supply throughout the product's life cycle.

This effort includes site-based analytical development teams across all operating units and regions that apply QbD principles to achieve robust analytical methodology. Laboratory operations across Wyeth also utilize integrated and harmonized systems to achieve industry-leading quality and efficiency. Meanwhile, Wyeth has brought together all elements of supply chain planning under one global organization, including planning, forecasting, inventory management, distribution and logistics. The focus is on improving, integrating and standardizing all supply chain processes and functions across the complete end-to-end supply chain from suppliers to patients.

Promoting Product Stability Best Practices

Whether you're taking *Rapamune* following an organ transplant or *Advil* for a headache, you expect the product to be effective wherever you live. That's why Wyeth continually tests the stability of its products by storing them in conditions that mimic the various climates where they'll be used – from the icy cold of Canada to the muggy heat of Brazil to the scorching dryness of Death Valley. This comprehensive effort is designed to accommodate the various climates of the more than 145 countries where we market our products.

In addition to focusing on our own products, Wyeth has become an industry leader by sharing best practices for evaluating and improving product stability. The Company actively participates in conferences on product stability as part of the American Association of Pharmaceutical Scientists



The counterfeit pharmaceutical business, estimated at \$40 billion, is expected to almost double over the next two years.

and is part of the stability expert team of Pharmaceutical Research and Manufacturers of America (PhRMA). As Wyeth expands throughout the globe, the importance of our product stability efforts will continue to grow.

Combating Drug Counterfeiting

Pharmaceutical counterfeiting is a global problem, putting at risk millions of patients who assume the medicines they take are safe and effective. The counterfeit pharmaceutical business currently is estimated at \$40 billion, a number that is expected to almost double over the next couple of years.

While the number of Wyeth incidents is relatively low, the Company has uncovered counterfeit versions of medicines such as *Prevnar* and *Effexor* and over-the-counter products such as *Centrum*, *Advil*, *Preparation H* and *ChapStick*.

In response to this growing problem, Wyeth's Global Security operation deploys cross-functional teams to investigate suspect counterfeit incidents. The teams, which include 10 to 12 investigators, review cases from the bottom up, working undercover in countries around the world. Global Security investigators also trace the movement of illegal products from distributors to consumers.

In addition, Wyeth created the Global Product Security Office to oversee worldwide anti-counterfeiting strategies and spearhead product-specific anti-counterfeiting initiatives, including:

- The upgrade of product packaging to incorporate both overt and covert anti-counterfeiting features that make products more difficult to copy and fakes easier to spot.
- The development of global coding technologies to comply with relevant anti-counterfeiting laws and to authenticate products before they reach customers, the last stop in product distribution.

Strengthening Practices of Governance and Compliance

Sound Corporate Governance

Sound principles of corporate governance have been, and continue to be, an important cornerstone in Wyeth's ability to secure the confidence of its stockholders, customers, employees and the patients we ultimately serve. Good corporate governance starts at the top, with both the management of the Company and members of our Board of Directors, who oversee the long-term interests of Wyeth and its stockholders.

Corporate governance has evolved at Wyeth. In the early part of this decade, before the popular focus on corporate governance reforms, Wyeth began evaluating both the formal and informal corporate governance policies that had been maintained by the Company for many years. A formal set of Board practices as well as corporate charters for each committee of the Board of Directors were adopted. Since the New York Stock Exchange announced new standards on corporate accountability and governance and the enactment of the Sarbanes-Oxley Act of 2002, the management of the Company and the Board of Directors have continued a robust evaluation process that, to date, has led to key positive advancements in our corporate governance, several of which were in response to stockholder requests.

The Company recognizes, however, that the scope of corporate governance has developed beyond the issues addressed by legislative and regulatory reforms in the United States. The field of corporate governance is a dynamic area that is rapidly evolving worldwide. With increased concern on the part of institutional investors,

international investment advisors and others about issues of sustainability, environmental protection, human rights, and universal access to products and services, good corporate governance is transforming into good corporate citizenship.

In light of all these challenges, Wyeth is committed to maintaining our solid foundation in good corporate governance and to participating in its evolutionary focus on good corporate citizenship.

“As corporate thought leaders and stakeholders contemplate the future of the planet, corporate governance is being more broadly defined, out of necessity, to encompass good corporate citizenship. Wyeth’s management and Board are acutely aware of the Company’s growing responsibilities to our world and have established a number of wide-ranging programs to not only do our part but to play a leadership role wherever we can.”

Eileen M. Lach
Vice President,
Corporate Secretary and
Associate General Counsel
Madison, N.J.

An Engaged Board of Directors

The Wyeth Board of Directors, made up predominantly of independent members, oversees and monitors the depth of our commitment to corporate citizenship both as a full Board and through the activities of the Corporate Issues Committee, which meets regularly and makes recommendations regarding relevant public and social issues. The committee monitors compliance, emerging trends and societal issues about which the Board believes the Company should act. The committee periodically reviews policies, practices and programs on issues such as the environment, health and safety, employment practices (including equal employment opportunity in hiring and promotion), charitable giving/community outreach, and political contributions and action.

Assuring Integrity through Our Code of Conduct

As a research-driven pharmaceutical and health care products company, we have the responsibility to provide safe and effective products to the medical professionals, customers and patients who depend on us. Our shareholders and colleagues also have high expectations that we will act with integrity in all that we do.

To guide all our employees, we have developed a comprehensive Code of Conduct, which has been translated into 22 languages, for all Wyeth employees. Wyeth's business partners and suppliers also are expected to adhere to the Code of Conduct for all activities performed on the Company's behalf, and Wyeth employees should inform these parties about our expectations.



Shown above is Wyeth headquarters in Madison, N.J.

The starting point for our Code is compliance with the law wherever we operate and with the requirements of the regulatory agencies that oversee all our activities. But the Code goes further, making it clear that we expect employees to function beyond the letter of the law and to operate according to the high standards of integrity and ethical behavior set by our mission and our values. In 2007, the Code was revised to provide additional information and explanations, including more specific information on antitrust compliance and security transactions and a gifts and entertainment policy that provides guidelines on contacts with vendors and service providers.

Policy on Interactions with Health Care Providers

As part of our Code of Conduct, Wyeth has articulated policies that are designed to help ensure that our interactions with health care professionals around the world meet our standards of ethics and integrity and comply with all applicable laws. These policies provide specific guidelines on topics such as Wyeth-sponsored meetings, medical communications, marketing activities, confidentiality of patient data and restrictions on gifts or payments. In all these endeavors, Wyeth strives to preserve the independence of the decisions made by health care professionals when prescribing for patients.

Charitable Contributions Policy

Wyeth's vision of leading the way to a healthier world includes providing support to organizations through financial contributions, product donations, patient assistance, volunteering and charitable partnerships. In these endeavors, Wyeth personnel may not make contributions to influence or reward the purchase of our products or to otherwise secure any business advantage. Charitable contributions must be made in full compliance with all applicable laws, including those of both the country of the donor and the recipient.

Proactive Compliance

To make sure that Wyeth fully complies with the myriad of regulations, laws and guidelines that apply to a global, research-based pharmaceutical company, the corporate audit staff, reporting directly to senior management, comes in direct contact with 80 percent of the Company's assets every year and the other 20 percent every other year.

This central team of 26 people focuses on performing financial reviews of the operations of country headquarters, manufacturing sites, research and development facilities, and sales offices. This team also coordinates efforts with other compliance organizations within Wyeth and assists with investigations of tampering and theft, as well as reviews of promotional activities and construction contracts.

“Our team of highly skilled and motivated professional auditors oversees Wyeth operations all over the world to ensure we comply with all financial laws and regulations as they relate to anything from sales activities to research and manufacturing processes. No stone is left unturned, and we're proud of our diligence.”

Andy Davidson
Vice President – Internal Audit
Madison, N.J.

Automation tools play an increasingly important role in Wyeth's auditing capabilities. A case in point is the use of two computer diagnostic tools that enable the group to analyze performance and assess risk across the Company's purchase-to-payment process by examining disbursements for potential fraud or other suspect activities. Sarbanes-Oxley compliance also is monitored more closely and efficiently through the use of automated self-assessment tools and web-based collaborative workspaces where information is shared. With these and other automation tools, Wyeth is migrating toward continuous auditing practices so the Company can periodically analyze selective financial transactions and monitor control points.

Ethical Advertising and Marketing Practices

Wyeth is committed to responsible sales, promotion and marketing practices with the goal of providing full and accurate information about our medicines and vaccines to meet the needs of physicians and patients.

Direct-to-consumer advertising about medicines can help educate patients about medical conditions and treatment options, especially for chronic conditions that affect large numbers of patients and for disorders that often are underdiagnosed or undertreated. Our effort to legitimately educate health care professionals is an important contribution to the health care community – educational opportunities that otherwise would not exist. To assure ethics in these endeavors, Wyeth has been at the forefront in adopting industry guidelines established by organizations such as the American Medical Association and PhRMA, among others.

Internally, the Company has established a formal compliance program, which we call Good Promotional Practices, and has a designated full-time Compliance Office. A Compliance Committee composed of senior executives of the Company's Pharmaceuticals division oversees the program. Our Code of Conduct (see page 44) also summarizes the ethical and legal standards to which all Wyeth employees must adhere in many areas, including the promotion, marketing and sale of our pharmaceutical products.

Participating in Public Policy Debates

Public policies have an enormous impact on our ability to discover, develop and distribute medicines and vaccines to meet patient needs and to create shareholder value. We take seriously our responsibility to participate in the political process and to provide our unique perspectives on the health care debate in the United States and other countries.



Wyeth makes its voice heard on relevant health care issues to provide our unique perspectives in policy debates in the United States and other countries.

Contributions to individual federal and state candidates are made only through the Company's Political Action Committee, as permitted by federal and state law. Through our nonpartisan Political Action Committee, eligible Wyeth employees can voluntarily pool their personal resources to support candidates who understand and appreciate the value of innovation and its importance to improving health care.

By law, all contributions made by the Political Action Committee at the federal level are publicly disclosed and available through the Federal Election Commission Web site at www.fec.gov. All contributions to state candidates are disclosed to the appropriate state authorities.

Wyeth also is working with influential thought leaders to shape the health policy agenda and related government decisions that will have an impact on the Company, patients who rely on our medicines and the research-based pharmaceutical industry. We support and promote specific public policies that are important to our future.

Affordability of Medicines

We firmly believe that pharmaceutical companies, operating in a competitive environment, are in the best position to develop innovative therapies to address the world's unmet medical needs. Wyeth also is committed to supporting patients who have difficulty affording their medications. We have a long history of helping uninsured patients in need receive our medications at no cost through the Wyeth Pharmaceutical Assistance Foundation, the Partnership for Prescription Assistance and other programs (see page 12). We also participate in numerous international programs promoting access to medicines and health care.

Uninsured and Universal Access to Health Insurance

Wyeth supports universal access to affordable health insurance, including meaningful coverage for prescription medicines with affordable out-of-pocket costs. To solve the problem of the uninsured, we believe that expanding and enhancing market-based health insurance, including coverage for medicines, are the best ways to improve affordability and achieve the goal of universal access to health insurance and care. Health care reforms that address only drug costs or prices will not improve access to care or the underlying reasons for lack of insurance.

Patient Comment

“Thank you very much for providing me with my prescription at a very reduced cost. Your Company is providing a much-needed service to uninsured people. Without your help, I would not be able to afford this medication. Thank you for this wonderful program.”

Sincerely, Virginia D.

Intellectual Property Protection

The perceived impact of product patents on access to medicines in poor nations is hotly debated. While access to health care is a complex issue, we believe the primary obstacles in many developing countries include the lack of a health care infrastructure and adequate health care financing – fundamental problems that should be a priority for international agencies and governments.

At the same time, wherever possible, Wyeth makes carefully planned product donations and considers flexible pricing terms to improve access to medicines. If patent exclusivity proves to be the sole barrier to drug access in a specific instance, we are committed to taking appropriate action case by case and collaborating with local and international partners to overcome such a barrier. We believe that health care companies will take the risks necessary to invest in the research needed to develop innovative medicines only when a reliable system of patent protection is in place.

Prescription Drug Importation

Wyeth believes that prescription drug importation is a threat to the safety and integrity of the U.S. medicine supply and poses unnecessary risks to patient health. Such a practice also is a backdoor way to impose pharmaceutical price controls in the United States, which would harm future innovation. Most experts believe that any cost reductions from drug importation would be negligible, as middlemen would likely realize the hypothetical savings. To increase access to necessary medicines, Wyeth supports efforts to expand and improve market-based health insurance, including coverage for prescription drugs, as well as efforts such as patient assistance programs, through which pharmaceutical manufacturers link individual patients to free or discounted medicines and assistance.

Using Effective Clinical Trial Practices

Wyeth conducts clinical trials worldwide to evaluate the safety and effectiveness of our products. These trials, required by regulatory agencies, are fundamental to the development of innovative medicines and vaccines. We understand the importance of communicating information about clinical trials as transparently as possible. As such, we make available a complete listing and overview of current research, searchable by condition, on the Wyeth Web site at www.wyeth.com/ClinicalTrialListings. This listing also is available at www.ClinicalTrials.gov, a registry and results database for federally and privately supported clinical research in human volunteers.

Wyeth performs these necessary clinical trials as consistently and uniformly as possible in order to maintain the highest scientific, regulatory and ethical standards. We also continually work with key stakeholders to find ways to improve the clinical trial process, striving to assess more effectively or efficiently a medicine's benefits and risks, protect clinical trial participants and increase the transparency of the clinical trial process.



Clinical trials, required by government regulations, help us evaluate the safety and effectiveness of our products and are fundamental to the development of innovative medicines.

Promoting the Humane Treatment of Animals

To conduct biomedical research effectively, all biopharmaceutical research companies are required to conduct laboratory experiments, animal studies and human clinical trials to establish the safety and efficacy of new drugs and to obtain government approval for their launch into the marketplace.

Research animals are essential to understand the complexities of our biology and the impact of drugs and vaccines on our organs and tissues. However, Wyeth Research is committed to using the minimum number of animals necessary to assess the safety and efficacy of our products. In addition, we use non-animal studies whenever valid alternatives exist, and we regularly refine testing methods to eliminate or minimize discomfort and distress to animals.

While non-animal research methods are increasingly reducing the need for animals, that need will continue for the foreseeable future. As such, we make sure that all animal care and use programs meet or exceed applicable regulations and guidelines and that all practices are conducted in a humane and scientifically sound manner. No procedures will be conducted with animals without written approval by the Institutional Animal Care and Use Committee, and experimental animals are housed and cared for in compliance with all U.S. and international humanitarian guidelines.

Wyeth animal care and use programs are led by specially trained veterinarians and professionals who are responsible for implementing sound animal management practices. All Wyeth employees involved in animal care and use must receive appropriate training and/or experience in the techniques and procedures of their respective fields, as well as the ethics of animal care.

Addressing Chronic Illness

According to the Centers for Disease Control and Prevention, more than 90 million Americans live with chronic illness. Evidence shows that these individuals are likely to incur high financial burdens for health care. As a leader in discovering and developing innovative medicines and as a large employer concerned with rising health care costs, Wyeth recognizes the impact that chronic diseases have on both individuals and society, and we have a long-standing commitment to helping ensure access to treatments and services that can benefit people living with these conditions.

Wyeth believes there is an opportunity for patients, advocacy groups, health care providers, employers, insurers and policymakers to work together toward solutions that improve the management of chronic diseases to preserve and enrich quality of life. Working collaboratively with various stakeholders, we are bringing interested parties together to develop practical solutions that will address the impact of out-of-pocket expenses on patients with chronic conditions and promote appropriate health care utilization, resulting in better health outcomes.



Wyeth is committed to improving the management of chronic diseases to preserve and enrich the quality of life for the more than 90 million sufferers in the United States.

Increasing Patient Awareness and Knowledge

By helping to educate and inform patients and caregivers about maintaining wellness, the nature of diseases and the best treatment options, we empower people to take care of their mental and physical health in the most fundamental ways. Wyeth does all this and more, providing updates on our clinical research and marketed products and working closely with many patient advocacy groups to promote health and wellness. On our Web site – www.wyeth.com – we also provide links to a network of Web sites for patients and caregivers. These links contain information, interactive health quizzes, downloadable tools and tips on a wide variety of health topics, including:

- Hemophilia
- Infants' and Children's Health
- Gastroesophageal Reflux Disease
- Rheumatoid Arthritis (RA)
- Vaccines
- Women's Health

Additionally, the Therapy Areas section of the Wyeth Web site can help patients learn more about specific health conditions. The section includes:

- A health illustrated encyclopedia – A comprehensive, updated knowledge base on more than 1,600 diseases and conditions, symptoms, tests, surgeries.
- In-depth reports – Extensive information on chronic diseases and wellness issues, including the latest information on treatments, risk factors, causes, diagnostic tests and preventive measures.
- Care guides – Step-by-step information on living with chronic conditions such as asthma, allergies, diabetes, high cholesterol, hypertension or obesity. Other guides focus on staying healthy to avoid chronic diseases.

Launching a Patient Education Program on Arthritis

For many of the more than 2 million Americans living with rheumatoid arthritis, the pain and fatigue every day make it seem like an almost insurmountable challenge. In May 2008, a series of radio interviews – organized, directed and sponsored by Wyeth to coincide with Arthritis Awareness Month – was designed to give RA patients new hope. Airing in cities nationwide, the interviews were part of an unbranded education campaign to inform people living with RA that they can lead active and full lives. The radio interviews featured Rain Perry, a popular folk singer, and her rheumatologist. Ms. Perry shared her personal experience of living with RA. Listeners who tuned in to the interviews were directed to www.insideRA.com to find more information or to locate a rheumatologist in their area.



Artist George Beach uses *Enbrel* to help control pain, swelling and other RA symptoms, allowing him to be active and productive.

Making Progress Each Day

At Wyeth, we continually look for sustainable ways to meet health care needs around the world – from getting treatments and services to people who need them to actively contributing to the steady progress of biopharmaceutical science to helping empower people to improve and maintain their health. We also will continue to work diligently to develop innovative medicines and vaccines for people in need.

Global health care issues, however, are very complex and challenging and require partnerships among all key stakeholders to achieve long-term goals. So we will listen and learn, embrace continuous change, understand society's expectations of us and work responsibly for the benefit of everyone who depends on us – patients, employees, investors and the communities where we work and live.

We pledge our conscientious citizenship, a helping hand and constructive actions that lead to a healthier world.



EHS Data Summary

	2000	2001	2002	2003	2004	2005	2006	2007	'00 to '07 Change
Total Sales (billion \$)	\$13.08	\$13.98	\$14.58	\$15.85	\$17.36	\$18.76	\$20.4	\$22.4	+71%
Safety									
Lost-Time Injury Case Rate	1.20	1.27	1.14	0.92	0.53	0.49	0.40	0.38	-68%
Total Injury Case Rate	1.98	2.29	1.83	1.44	1.08	1.02	0.82	0.86	-57%
Energy Use									
Energy Use (million gigajoules)	13.5	13.7	14.1	14.2	14.5	14.4	14.1	14.4	+7%
Energy Use (million joules/thousand \$)	1,032.1	980.0	967.1	895.9	835.3	767.6	790.5	644.3	-38%
CO ₂ Emissions (million kg)	1,080	1,114	1,152	1,172	1,170	1,161	1,143	1,157	+7%
CO ₂ Emissions (million kg/billion \$)	82.6	79.7	79.0	73.9	67.4	61.9	56.0	51.7	-37%
Water Use									
Water Use (million L)	12,978	13,048	12,834	12,844	13,195	13,719	13,588	12,459	-4%
Water Use (million L/billion \$)	992.2	933.3	880.3	810.5	760.1	731.3	666.1	556.2	-44%
Air Emissions									
Ozone Depleting Substance Releases (kg)	12,303	16,182	11,815	10,034	10,279	10,494	14,916	9,527	-23%
Ozone Depleting Substance Releases (kg/billion \$)	940.6	1,157.5	810.4	633.0	592.2	559.5	731.2	425.3	-55%
Permitted Air Emissions ¹ (million kg)	1.49	1.63	2.10	2.28	1.38	1.40	1.40	1.59	+7%
Permitted Air Emissions ¹ (million kg/billion \$)	0.11	0.12	0.14	0.14	0.08	0.08	0.07	0.07	-36%
Hazardous Waste									
Hazardous Waste Generation (million kg)	29.8	33.6	31.5	21.0	12.0	12.3	14.8	16.4	-50%
Hazardous Waste Disposal (million kg)	14.0	16.1	13.5	9.9	9.4	9.0	10.4	11.5	-18%
Hazardous Waste Recycled (million kg)	15.8	17.4	17.9	11.1	2.6	3.3	4.4	4.9	-69%
Hazardous Waste Generation (million kg/billion \$)	2.28	2.40	2.16	1.35	0.69	0.66	0.73	0.73	-67%
Hazardous Waste Disposal (million kg/billion \$)	1.07	1.15	0.93	0.65	0.54	0.48	0.51	0.51	-52%
Hazardous Waste Recycled (million kg/billion \$)	1.21	1.25	1.23	0.72	0.15	0.18	0.22	0.22	-82%
Solid Waste									
Solid Waste Generation (million kg)	91.2	102.0	99.1	69.2	50.1	52.0	54.4	49.2	-46%
Solid Waste Disposal (million kg)	27.0	22.0	23.7	24.4	22.8	22.7	22.7	21.4	-21%
Solid Waste Recycled (million kg)	64.2	80.6	75.5	44.8	27.3	29.3	31.7	27.4	-57%
Solid Waste Generation (million kg/billion \$)	6.97	7.34	6.80	4.37	2.86	2.77	2.66	2.20	-68%
Solid Waste Disposal (million kg/billion \$)	2.06	1.58	1.62	1.54	1.29	1.21	1.11	0.96	-53%
Solid Waste Recycled (million kg/billion \$)	4.91	5.76	5.18	2.83	1.57	1.56	1.55	1.22	-75%
SARA									
Chemicals Used (million kg)	3.93	3.23	1.49	1.88	1.66	1.39	1.42	1.30	-67%
Chemicals Used (million kg/billion \$)	0.296	0.228	0.738	0.119	0.096	0.074	0.070	0.058	-80%
SARA 313 Releases (kg)	37,827	31,854	7,450	14,103	7,705	6,259	5,094	8,074	-79%
SARA 313 Releases (kg/billion \$)	2,892	2,279	511	890	444	334	250	360	-88%
Wastewater Discharges									
Wastewater Discharge (million L)	8,699	8,513	7,750	7,838	7,855	8,352	7,876	9,026	+4%
Wastewater Discharge (million L/billion \$)	655.90	602.53	531.40	494.50	452.51	445.31	386.08	402.95	-39%

¹ Permitted air emissions include carbon monoxide, nitrogen oxides, sulfur oxides, volatile organic compounds, dust and particulate matter, and lead.
Please note that we have revised some historical data. The changes are minor and do not significantly affect the data trends.

kg = kilogram
L = liter
CO₂ = carbon dioxide

We hope that this 2008 Wyeth Corporate Citizenship Report meets your needs for information on our programs and performance. In order to improve the quality of future reports, please complete and return this reply card. We value your feedback.

What did you like about this report? _____

How can we improve future reports? _____

The report length was:	<input type="radio"/> too long	<input type="radio"/> appropriate	<input type="radio"/> too short
The statistical information was:	<input type="radio"/> too detailed	<input type="radio"/> appropriate	<input type="radio"/> not detailed enough
Examples of actions taken or planned were:	<input type="radio"/> too detailed	<input type="radio"/> appropriate	<input type="radio"/> not detailed enough
Information on our policies and programs was:	<input type="radio"/> too detailed	<input type="radio"/> appropriate	<input type="radio"/> not detailed enough

Name: _____

Title: _____

Affiliation: _____


Address: _____

Phone: _____ E-mail: _____

Please send me ____ additional copies of this report.



NO POSTAGE
NECESSARY
IF MAILED
IN THE
UNITED STATES



BUSINESS REPLY MAIL
FIRST CLASS PERMIT PERMIT NO. 104 MADISON, NJ

POSTAGE WILL BE PAID BY ADDRESSEE

Wyeth
Public Affairs
Five Giralda Farms
Madison, NJ 07940

Mission & Vision

Mission

We bring to the world pharmaceutical and health care products that improve lives and deliver outstanding value to our customers and shareholders.

Vision

Our vision is to lead the way to a healthier world. By carrying out this vision at every level of our organization, we will be recognized by our employees, customers and shareholders as the best pharmaceutical company in the world, resulting in value for all.

We will achieve this by:

- Leading the world in innovation through pharmaceutical, biotech and vaccine technologies
- Making trust, quality, integrity and excellence hallmarks of the way we do business
- Attracting, developing and motivating our people
- Continually growing and improving our business
- Demonstrating efficiency in how we use resources and make decisions

Stock Trading Information

Wyeth stock is listed on the New York Stock Exchange (ticker symbol: WYE).

Values

To achieve our mission and realize our vision, we must live by our values:

Quality

We are committed to excellence – in the results we achieve and in how we achieve them.

Integrity

We do what is right for our customers, our communities, our shareholders and ourselves.

Respect for People

We promote a diverse culture and a commitment to mutually respect our employees, our customers and our communities.

Leadership

We value people at every level who lead by example, take pride in what they do and inspire others.

Collaboration – “Teamwork”

We value teamwork – working together to achieve common goals is the foundation of our success.

Equal Employment Opportunity

Our established affirmative action and equal employment programs demonstrate our long-standing commitment to provide job and promotional opportunities for all qualified persons regardless of age, color, disability, national origin, race, religion, sex, sexual orientation, status as a Vietnam-era veteran or a special disabled veteran, or any military uniformed services obligation.

This report includes forward-looking statements. All statements that are not historical facts are forward-looking statements. All forward-looking statements address matters involving numerous assumptions, risks and uncertainties that could cause actual results to differ materially from those expressed or implied by those statements. In particular, the Company encourages the reader to review the risks and uncertainties described under the heading “Item 1A. RISK FACTORS” in the Company’s 2008 Annual Report on Form 10-K. The forward-looking statements in this report are qualified by these risk factors. Accordingly, the Company cautions the reader not to place undue reliance on these forward-looking statements, which speak only as of the date on which they were made, and the Company undertakes no obligation to update or revise any of these statements, whether as a result of new information, future developments or otherwise.

Wyeth

Five Giralda Farms
Madison, NJ 07940
(973) 660-5000